SFM
RNTX

Sphera Funds Management’s Rein Therapeutics RNTX Stock Holding History

Sphera Funds Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6,250
Closed -$1.32M – 149
2017
Q4 		$1.32M Hold
6,250
– – 0.15% 108
2017
Q3 		$1.67M Hold
6,250
– – 0.24% 92
2017
Q2 		$1.39M Buy
+6,250
New +$1.37M 0.24% 101

Other funds holding RNTX

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ECM
Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sphera Funds Management's RNTX Position: Q1 2018 in Review

Sphera Funds Management sold out of Rein Therapeutics (RNTX) in Q1 2018, closing a stake of 6,250 shares — an estimated $1.32M sold.

Sphera Funds Management first reported a position in RNTX in Q2 2017 and held it in 3 quarters. The position peaked at $1.67M in Q3 2017. 27 funds tracked by Wall St. Rank hold RNTX as of Q1 2018.

  • Sphera Funds Management reported no remaining Rein Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Sphera Funds Management sold 6,250 Rein Therapeutics shares in Q1 2018, an estimated $1.32M.
  • Sphera Funds Management first reported a position in Rein Therapeutics in Q2 2017 and held it in 3 quarters.
  • Sphera Funds Management's Rein Therapeutics position peaked at $1.67M in Q3 2017.
  • 27 funds tracked by Wall St. Rank held Rein Therapeutics as of Q1 2018.

Based on Sphera Funds Management's 13F filing for Q1 2018, filed 10 May 2018.